Noile-Immune Biotech Inc. logo

Noile-Immune Biotech Inc.

Noile-Immune Biotech is a clinical stage biotechnology company focused on the development and commercialization of next generation CAR-T cells to eradicate solid cancers.

Noile-Immune has an exclusive license to platform Prime CAR-T technology for the development of next generation CAR-T cell therapy, and was developed by Professor Koji Tamada at Yamaguchi University. He is also founder director of Noile-Immune.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.noile-immune.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
7-17-2 Ginza, Chuo-ku, 104-0061
Tokyo
Japan
Email
Contact Number

Noile-Immune Biotech is partnered with the National Cancer Center Japan and Yamaguchi University to improve the accuracy in R&D and in faster clinical trials.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Noile-Immunes Prime CAR-T technology: Proliferation-inducing and migration-enhancing technology utilizes cytokine and chemokine and has been expected it exert more effective for cancer therapy in solid tumor.

In Sep 2017, Takeda Pharmaceutical and Noile-Immune entered into a collaboration to develop next generation chimeric antigen receptor T cell therapy (CAR-T). Under the terms, Takeda made an equity investment and a technology access payment to Noile-Immune, in turn Takeda acquired an exclusive options to obtain licensing rights for the development and commercialization of Noile-Immunes pipeline and products resulting from this partnership. Additional terms remains undisclosed.